KRAS and non-small cell lung carcinoma: In another cohort of 1194 patients with KRAS-mutated NSCLC treated at the Memorial Sloan Kettering Cancer Center, KRASG12C and other KRAS mutations (15% G12D, 16% G12V, 8% G12A, 4% G13D) had similar comutation patterns and outcomes with similar response rates between patients with KRASG12C or other KRAS mutations in patients with PD-L1 higher than 50% (n = 103, 40% vs. 58%, p = 0.06) [60].